Odanacatib Pharmacokinetics Comparison Between Chinese and Non-Chinese Postmenopausal Women
Author:
Affiliation:
1. Peking Union Medical College Hospital; Clinical Pharmacological Research Center; Beijing China
2. Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs; Beijing China
3. Merck & Co., Inc. ; Kenilworth NJ USA
Funder
Merck
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.434/fullpdf
Reference16 articles.
1. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density;Bone;J Bone Miner Res.,2010
2. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect;Eisman;J Bone Miner Res,2011
3. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study;Langdahl;J Bone Miner Res,2012
4. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis-a double-blind, randomized, dose-finding study;Nakamura;Osteoporos Int,2014
5. Merck &Co. drops osteoporosis drug odanacatib;Mullard;Nat Rev Drug Discov.,2016
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Estrone-targeted liposomes for mitoxantrone delivery via estrogen receptor: In vivo targeting efficacy, antitumor activity, acute toxicity and pharmacokinetics;European Journal of Pharmaceutical Sciences;2021-06
2. Chemoenzymatic Synthesis of an Odanacatib Precursor through a Suzuki‐Miyaura Cross‐Coupling and Bioreduction Sequence;ChemCatChem;2019-09-25
3. In silico Guided Drug Repurposing: Discovery of New Competitive and Non-competitive Inhibitors of Falcipain-2;Frontiers in Chemistry;2019-08-06
4. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis;British Journal of Clinical Pharmacology;2019-03-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3